In pancreatic ductal adenocarcinoma, FAP-positive CAFs suppressed the effects of anti-PD-L1 treatment through CXCL12/CXCR4 signalling [35]. This evidence concerns the gene CXCR4 and pancreatic ductal adenocarcinoma.